Cefiderocol: Mechanism, Activity, Resistance, and Pharmacokinetics

Cefiderocol is an injectable antibiotic that sneaks into bacterial cells by disguising itself as something bacteria desperately need: iron. Structurally, it combines a cephalosporin core (the part that kills bacteria by blocking cell-wall construction) with a siderophore side chain (the part that mimics the iron-scavenging molecules bacteria produce naturally). This “Trojan horse” design lets the drug bypass several of the defenses that make multidrug-resistant gram-negative infections so difficult to treat, and it remains active against organisms carrying nearly every known class of beta-lactamase enzyme, including the carbapenemases that defeat last-resort carbapenems.

How the Trojan Horse Entry Works

Bacteria living in the human body face a constant shortage of free iron, which they need for basic metabolism. To scavenge it, they produce small molecules called siderophores that bind iron tightly and then get pulled back inside the cell through dedicated transporter proteins on the outer membrane. Cefiderocol exploits this system. Its chlorocatechol group at the end of the C-3 side chain chelates iron in the surrounding environment, and the iron-drug complex is recognized by the same outer-membrane transporters the bacterium uses to import its own siderophores.¹ Once inside the periplasmic space (the zone between the two membranes of a gram-negative bacterium), the cephalosporin half of the molecule binds to penicillin-binding protein 3, halting cell-wall assembly and eventually killing the cell.²

The practical payoff is that cefiderocol enters the cell through active iron transport rather than relying on the porin channels that many other beta-lactams use. This matters because porin loss and efflux-pump overexpression are two of the most common tricks multidrug-resistant bacteria deploy to keep antibiotics out.³ Because cefiderocol sidesteps both routes, those defenses lose much of their protective value.

Studies in Pseudomonas aeruginosa confirmed that the drug forms a chelating complex with ferric iron and is actively transported into the cell via iron transporters. When researchers modified one of the hydroxyl groups on the catechol moiety, the enhanced iron transport disappeared, confirming that the siderophore structure is essential to the mechanism rather than incidental.⁴

Spectrum of Activity Against Resistant Gram-Negative Bacteria

Cefiderocol’s value lies primarily in its coverage of the hardest-to-treat gram-negative organisms, the ones resistant to carbapenems. Its structural design gives it stability against all four Ambler classes of beta-lactamases (A through D), including KPC, NDM, VIM, IMP, and OXA-48-type carbapenemases.⁵ That breadth is unusual. Most newer beta-lactam/inhibitor combinations handle some of these enzyme classes but not all. Cefiderocol also covers difficult nonfermenting organisms like Acinetobacter baumannii, Stenotrophomonas maltophilia, and Burkholderia cepacia, which sit outside the reach of many standard regimens.⁶

Large surveillance studies have put numbers on that coverage. In a collection of isolates from US and European hospitals gathered between 2020 and 2021, cefiderocol inhibited about 97% of carbapenem-nonsusceptible Enterobacterales by CLSI breakpoints and was the only tested agent active against isolates carrying metallo-beta-lactamase carbapenemases or multiple carbapenemase genes. Against multidrug-resistant P. aeruginosa and A. baumannii subsets carrying carbapenemases, susceptibility rates were above 97%.⁷

A UK-based study looking specifically at multidrug-resistant isolates found that at a concentration of 4 mg/L, cefiderocol inhibited about 92% of all Enterobacterales tested, with rates of 95–100% against isolates carrying AmpC with porin loss, VIM, IMP, OXA-48-like, KPC, or GES enzymes. The main soft spots were NDM-producing strains (about 72% inhibited) and ESBL producers with porin loss (about 89%).⁸ That relative weakness against NDM producers is a recurring theme across studies and worth keeping in mind when choosing therapy.

How Resistance Develops

No antibiotic stays untouchable forever, and cefiderocol is no exception. A systematic review of resistance mechanisms found that bacteria typically need multiple defenses working together to resist cefiderocol. The most common combination involves certain beta-lactamases (especially NDM, KPC, and mutant AmpC enzymes) paired with porin mutations or changes in siderophore-receptor proteins.⁹ Additional mechanisms that have been documented include efflux-pump upregulation and modifications to penicillin-binding protein 3, the drug’s cellular target.

The most striking resistance pathway involves disabling the very iron transporters that cefiderocol hijacks. In a laboratory experiment, researchers serially exposed an NDM-producing Klebsiella pneumoniae strain to cefiderocol and eventually obtained a mutant whose minimum inhibitory concentration (the lowest drug concentration that stops growth) soared to above 128 µg/mL. The culprit was an early stop codon in cirA, a gene encoding an iron transporter. When the researchers restored a working copy of cirA, susceptibility returned to normal.¹⁰ In other words, the bacterium shut down its own iron-import door rather than let the Trojan horse through. Whether that trade-off — losing iron uptake efficiency to survive the antibiotic — is sustainable for bacteria in the iron-starved environment of the human body is an open question, but the finding shows that resistance can develop rapidly under pressure.

Real-world emergence of resistance has been documented, though so far it appears uncommon in surveillance data. In one small case series of severely infected patients, two out of ten initially susceptible strains developed cefiderocol resistance during treatment.¹¹ That figure should be read cautiously given the tiny sample size, but it reinforces the importance of susceptibility monitoring during prolonged courses.

Pharmacokinetics and Dosing Basics

Cefiderocol binds to plasma proteins (mainly albumin) at a moderate rate of roughly 40–60%, and its elimination half-life in healthy adults runs about two to three hours. The kidneys handle the bulk of clearance, which means renal function is the dominant variable that determines drug levels in any given patient.¹²

Like other cephalosporins, the best predictor of whether cefiderocol will work against a given infection is the fraction of the dosing interval during which the free (unbound) drug concentration in the blood stays above the pathogen’s minimum inhibitory concentration.¹³ Animal infection models confirmed this, showing that time above MIC correlated with efficacy better than peak concentration or total drug exposure did. Those models also found that MIC values measured in iron-depleted broth predicted real-world efficacy more accurately than values measured in standard broth, reflecting the iron-dependent entry mechanism.¹⁴

The standard dosing regimen for adults with normal kidney function is 2 g given intravenously every 8 hours as a 3-hour infusion. Simulations showed that this regimen achieved adequate drug levels against organisms with MICs up to 4 µg/mL in over 90% of virtual patients.¹⁵

Adjusting Doses for Kidneys That Are Too Slow or Too Fast

Because cefiderocol leaves the body primarily through the kidneys, patients on both ends of the renal-function spectrum need dose modifications. For those with moderate to severe kidney impairment, doses are reduced to avoid drug accumulation.¹⁶

At the other extreme, critically ill patients sometimes develop augmented renal clearance, where kidneys filter much faster than normal. For these patients, the standard every-8-hours regimen may not keep drug levels high enough. Modeling suggests that bumping the frequency to 2 g every 6 hours over 3-hour infusions restores adequate coverage.¹⁷

Patients receiving continuous renal replacement therapy (CRRT), a form of around-the-clock dialysis used in intensive care, present a particular dosing puzzle. Cefiderocol is the only antibiotic with FDA-approved dosing recommendations based on effluent flow rate, the rate at which fluid passes through the dialysis filter. Depending on that flow rate, the recommended dose ranges from 1.5 g every 12 hours up to 2 g every 8 hours.¹⁸ A practical wrinkle is that effluent flow rates often change during CRRT. A retrospective assessment found that within the first 24 hours of CRRT, the flow rate shifted enough to warrant a cefiderocol dose change in about 38% of patients. The most affected group were patients starting at the lowest flow rates: 70% of them had flow rates rise to a level requiring dose escalation within a day.¹⁸ That kind of variability means clinicians need to reassess dosing frequently rather than setting it once at the start of dialysis.

Clinical Trial Evidence

Cefiderocol’s pivotal efficacy data come from two key randomized trials with quite different designs and patient populations. In the APEKS-NP trial, which enrolled patients with gram-negative nosocomial pneumonia (most of whom had carbapenem-susceptible pathogens), cefiderocol was compared head-to-head with high-dose extended-infusion meropenem. Day 14 all-cause mortality was about 12% in both groups, meeting the trial’s non-inferiority endpoint. Rates of adverse events were also similar between the two arms.¹⁹ A post-hoc analysis of that same trial found that cefiderocol treatment did not disturb iron balance in the body — an early concern given the drug’s iron-chelating mechanism. Changes in serum iron, hepcidin, transferrin saturation, and iron-binding capacity were similar between cefiderocol and meropenem arms, and rates of anemia-related adverse events were essentially identical at about 18% in each group.²⁰

The more contentious trial was CREDIBLE-CR, which enrolled patients with documented carbapenem-resistant infections and randomized them to cefiderocol or best available therapy (usually colistin-based regimens). Clinical cure rates were similar between the groups, but all-cause mortality was numerically higher with cefiderocol: roughly 25% versus 18% at day 28. The excess mortality was concentrated among patients with Acinetobacter infections, where cefiderocol-treated patients had a mortality rate of about 50% compared with 18% in the best-available-therapy group. Patients with complicated urinary tract infections, by contrast, trended in the opposite direction. The reason for the mortality imbalance in Acinetobacter infections remains unclear. Some experts have pointed to sicker baseline populations in the cefiderocol arm, others to possible treatment-emergent resistance, and the trial was too small to settle the question. The finding prompted a boxed warning in the US prescribing information and has shaped how clinicians think about using cefiderocol for Acinetobacter pneumonia and bloodstream infections.

What Real-World Use Looks Like

Post-marketing data have been accumulating, and the picture is more encouraging than the CREDIBLE-CR mortality signal might suggest, though the patient populations remain severely ill with high baseline mortality risk. Interim US results from the PROVE registry, which tracked 244 patients treated with cefiderocol in clinical practice, reported clinical cure in about 65% of patients and clinical response in about 74%. Thirty-day in-hospital all-cause mortality was about 18%, and only five patients experienced adverse drug reactions attributed to cefiderocol, including one serious case of interstitial nephritis.²¹

A retrospective study focused on critically ill patients with multidrug-resistant gram-negative infections found overall mortality of about 47%, but that figure reflected the severity of the underlying conditions: septic shock and colonization by multiple resistant organisms were the strongest predictors of death, not the drug itself. No serious drug-related adverse events were reported, and cefiderocol performed best in bloodstream and soft-tissue infections.²² Across all of these datasets, cefiderocol’s tolerability profile has been consistently favorable, with serious adverse events attributable to the drug remaining rare.

Why Susceptibility Testing Is Unusually Complicated

Testing whether a bacterial isolate is susceptible to cefiderocol is harder than for most other antibiotics, and this is a genuine headache for clinical laboratories. The issue goes back to the drug’s iron-dependent entry mechanism. Standard laboratory broth contains enough free iron to partially block cefiderocol from entering bacterial cells the way it would in the body (where free iron is scarce). If you test the drug in ordinary broth, MIC values come out artificially high and underpredict clinical activity.²³

The reference method requires iron-depleted cation-adjusted Mueller-Hinton broth, which labs prepare by treating the broth with a chelating resin to strip out iron. But even this process produces variable results depending on the brand of broth used and how long the chelation step runs. A recent evaluation testing 85 gram-negative isolates across four commercially available broth sources found that while MIC reproducibility was high within each brand, different brands produced reproducibly different MIC values for the same isolate. Extending the chelation time to six hours achieved optimal iron depletion across all brands, and two specific media sources (BD-BBL and BD-Difco) showed the best agreement with each other and the best correlation with actual efficacy in animal models.²⁴ Updated guidelines now incorporate the longer chelation time and refined reading rules for a phenomenon called “trailing,” where growth does not drop off sharply at the MIC endpoint. These seem like dry technical details, but in practice they determine whether a laboratory reports an isolate as susceptible or resistant, which directly influences whether a patient gets cefiderocol or a different drug.

Combination Therapy and Synergy

Given the severity of infections where cefiderocol is used and the ever-present worry about resistance emergence, there is growing interest in pairing cefiderocol with other agents. In vitro synergy testing against highly drug-resistant Acinetobacter baumannii isolates found that cefiderocol alone was active against about two-thirds of strains, but combining it with ceftazidime-avibactam produced synergy in 100% of strains, and combining it with sulbactam-durlobactam produced synergy in about 95%.²⁵

Broader testing across carbapenem-resistant Enterobacterales, P. aeruginosa, and A. baumannii found that pairing cefiderocol with beta-lactamase inhibitors (avibactam, sulbactam, or tazobactam) enhanced its activity even against isolates already resistant to cefiderocol alone. The cefiderocol-sulbactam combination stood out as the most broadly effective pairing, boosting activity against all three organism groups, while cefiderocol-avibactam worked best against carbapenem-resistant Enterobacterales specifically.²⁶ These are laboratory findings, and prospective clinical trials comparing monotherapy to combinations have not yet been completed, so the practical benefit in patients remains to be confirmed.

Pediatric Pharmacokinetics

Data on cefiderocol in children are still limited but emerging. The PEDI-CEFI phase 2 study enrolled hospitalized patients from three months to under 18 years old who were already receiving standard antibiotics for various infections. Children received either a single dose or multiple doses of cefiderocol alongside their existing treatment. Plasma drug levels were reassuringly consistent across age groups and body weights in children with normal or mildly impaired kidney function. Peak concentrations after multiple doses ranged from roughly 89 to 106 µg/mL, and trough concentrations at 8 hours ranged from about 10 to 18 µg/mL. No deaths, no cefiderocol-related serious adverse events, no clinically significant lab abnormalities, and no treatment discontinuations were reported.²⁷ Pediatric efficacy trials are still needed, but the pharmacokinetic and safety data so far suggest that adult dosing principles can reasonably be adapted for children, with weight-based adjustments.

Getting Into the Lungs

Pneumonia accounts for a large share of the infections where cefiderocol is used, so how well the drug penetrates lung tissue matters. A pharmacokinetic modeling study measured cefiderocol concentrations in epithelial lining fluid (ELF), the thin layer of liquid that coats the inner surface of the airways where bacteria in pneumonia actually live. In patients with pneumonia, the ratio of drug concentration in ELF to free drug in plasma was about 0.34, roughly 1.4 times higher than in healthy volunteers.²⁸ That penetration ratio is in the same neighborhood as other cephalosporins, and the higher ratio in inflamed lungs (compared to healthy lungs) is a common and helpful pattern seen with many beta-lactams: the inflammation of pneumonia increases blood-vessel permeability, which lets more drug seep into the airway. Combined with the low free-iron environment of the lung, which favors cefiderocol’s active uptake mechanism, these concentrations support the drug’s use in pneumonia, consistent with the APEKS-NP trial results showing non-inferiority to meropenem for nosocomial pneumonia.